gdc
FDA Approvals, News & UpdatesNewsworthy

Actemra First Treatment Approved for CAR T-Cell–Induced Cytokine-Release Syndrome

December 2017 Vol 3 No 6

On August 30, 2017, in association with the approval of the first CAR T-cell therapy (Kymriah), the FDA approved a new use for Actemra (tocilizumab; from Genentech), a humanized IL-6 receptor antagonist, for CAR T-cell–induced severe or life-threatening cytokine-release syndrome in patients older than 2. Cytokine-release syndrome can be caused by immune-cell therapy, such as CAR T-cell therapy.

This approval was based on a clinical trial showing the benefits of Actemra in patients with cytokine-release syndrome. Overall, 69% of patients had a response to Actemra within 14 days of treatment, meaning that the cytokine-release syndrome was resolved.

Serious side effects with Actemra include risk of serious infections and certain cancers, tears in the stomach, thrombocytopenia, neutropenia, hepatitis B infection, serious allergic reactions, and central nervous system problems.

Recommended For You
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country